4.93
0.07 (1.44%)
| Penutupan Terdahulu | 4.86 |
| Buka | 4.83 |
| Jumlah Dagangan | 1,201,139 |
| Purata Dagangan (3B) | 1,827,214 |
| Modal Pasaran | 688,541,888 |
| Harga / Jualan (P/S) | 64.26 |
| Harga / Buku (P/B) | 4.21 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -1,222.27% |
| EPS Cair (TTM) | -1.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -39.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.72% |
| Nisbah Semasa (MRQ) | 5.06 |
| Aliran Tunai Operasi (OCF TTM) | -12.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.41 M |
| Pulangan Atas Aset (ROA TTM) | -18.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -91.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Aclaris Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.69% |
| % Dimiliki oleh Institusi | 88.24% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |